Back to drug safety directory
Anxiolytic (5-HT1A partial agonist)Reviewed May 15, 2026

Buspirone (Buspar) and Ketamine Therapy | Tovani Health

Buspar (Buspirone)Anxiolytic (5-HT1A partial agonist)

Verdict at Tovani Health

Fully compatible with KAP.

Buspirone and ketamine have no clinically significant interaction. The older theoretical serotonin syndrome concern (buspirone is a 5-HT1A partial agonist) is not supported by any published combination cases with ketamine, which is not meaningfully serotonergic itself. Continue as normal.

If you take Buspar regularly and are considering at-home ketamine therapy, the combination is generally safe at therapeutic doses. This page covers the brief pharmacologic context and what we do at intake.

How Buspar interacts with ketamine

Buspirone partially activates 5-HT1A receptors and has weak D2 antagonism. It is not sedating or addictive. Metabolized by CYP3A4. No documented serotonin syndrome with ketamine.

What we do at intake

Disclose dose and timing. If you take CYP3A4 inhibitors (like grapefruit juice or clarithromycin), buspirone levels can spike; tell us about those.

Bottom line

Buspirone and ketamine have no clinically significant interaction. The older theoretical serotonin syndrome concern (buspirone is a 5-HT1A partial agonist) is not supported by any published combination cases with ketamine, which is not meaningfully serotonergic itself. Continue as normal.

Frequently Asked Questions

Is buspirone better than a benzo for anxiety during KAP?

Yes from a ketamine-response standpoint. Buspirone does not carry the chronic-benzo response-blunting concern.

Ready to find out if at-home ketamine fits your situation?

We’ll note that you’re on Buspar (Buspirone) at intake. The eligibility check takes 5 minutes and gives you an honest answer about whether at-home ketamine fits your specific situation.

FL and NJ residents only. Benjamin Soffer, DO — Tovani Health.

Sources

The verdict and clinical guidance on this page are based on the following peer-reviewed literature and FDA prescribing information.

  1. Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review. Veraart JKE, Smith-Apeldoorn SY, Bakker IM, et al.. International Journal of Neuropsychopharmacology. 2021. PMID: 34170315

    Systematic review of pharmacodynamic interactions between ketamine and psychiatric medications used in depression treatment.

  2. Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis. Alnefeesi Y, Chen-Li D, Krane E, et al.. Journal of Psychiatric Research. 2022. PMID: 35688035

    Meta-analysis of 2,665 patients across 79 studies — 45% response and 30% remission with ketamine in treatment-resistant depression.

Clinically reviewed

Reviewed by Benjamin Soffer, DO on May 15, 2026. Dr. Soffer is a board-certified physician (American Board of Internal Medicine) licensed in Florida and New Jersey, prescribing at-home ketamine therapy through Tovani Health.

This page is general information about how this medication interacts with at-home ketamine therapy at Tovani Health. It is not a substitute for medical advice from your prescribing physician about your specific situation. Always discuss medication changes with the doctor who prescribed them.